Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Altheus Therapeutics Inc. Stories

2014-02-26 08:28:31

OKLAHOMA CITY, Feb. 26, 2014 /PRNewswire/ -- Altheus Therapeutics, Inc., announced completion of dosing in ZA201, a double-blind, active-controlled Phase 2 trial evaluating the efficacy and safety of Zoenasa® Rectal Gel versus mesalamine enema in 120 patients with left-sided ulcerative colitis. The primary endpoint of ZA201 is reduction in the Ulcerative Colitis Disease Activity Index (UCDAI) at 6 weeks. Secondary endpoints include endoscopic remission, reduction in UCDAI at 3...

2014-01-29 12:27:38

OKLAHOMA CITY, Jan. 29, 2014 /PRNewswire/ -- Altheus Therapeutics, Inc. announced the USPTO has allowed patent 8,629,127 B2 covering the oral pharmaceutical composition 5-ASA (5-aminosalicylic acid) and NAC (N-acetylcysteine). Combination therapy patents are uncommon and under-appreciated in the pharmaceutical industry because the Patent Office requires surprising, unexpected, or synergistic benefits from combining active ingredients into a single formulation. Altheus' success in...

2014-01-09 08:28:44

OKLAHOMA CITY, Jan. 9, 2014 /PRNewswire/ -- Altheus Therapeutics, Inc., announced that it has completed enrollment for ZA201, a 6-week, double-blind, active-controlled Phase 2 clinical trial of the efficacy and safety of Zoenasa® Rectal Gel in approximately 120 adult patients with left-sided, or distal, ulcerative colitis. Topline results are expected in to be available in March or early April. (Logo: http://photos.prnewswire.com/prnh/20140109/DA43446LOGO) "Positive ZA201...

2012-08-28 06:28:53

OKLAHOMA CITY, Aug. 28, 2012 /PRNewswire/ -- Altheus Therapeutics announced today it has randomized its first patient in a comparator-controlled Phase 2 efficacy study of Zoenasa®, a novel combination therapy for ulcerative colitis (UC). Zoenasa is a fixed-dose combination of mesalamine (current standard of care in UC) plus a second potent anti-inflammatory agent not previously used in this indication. In multiple animal models and one human study the combination has shown to be...

2011-01-06 07:00:00

OKLAHOMA CITY, Jan. 6, 2011 /PRNewswire/ -- Altheus Therapeutics, Inc., announced that it has completed a two dose, double-blind, active-controlled Phase I clinical trial of the safety and tolerability of Zoenasa(TM) Rectal Suspension in adult patients with left-sided, or distal, ulcerative colitis. No serious adverse events were experienced by patients in this study. "We are excited to have achieved this milestone, as it prepares Altheus to begin our planned Phase II clinical program to...